Craft

AstraZeneca

Stock Price

£115.3

2024-10-29

Market Capitalization

£2 B

2024-08-23

Revenue

$58.7 B

FY, 2025

AstraZeneca Summary

Company Summary

Overview
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. It develops drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, gastroenterology, and other areas. The company offers its products to primary care and specialty care physicians.
Type
Public
Status
Active
Founded
1999
HQ
Cambridge, GB | view all locations
Website
https://www.astrazeneca.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Pascal Soriot

    Pascal Soriot, Executive Director and Chief Executive Officer

    • Johan Hyllner

      Johan Hyllner, Executive Director and Head of Cell Therapy, BioPharmaceuticals R&D

    • Hitesh Sanganee

      Hitesh Sanganee, Head of Emerging Innovations

    • Pam Cheng

      Pam Cheng, Executive Vice-President, Operations, Information Technology and Sustainability

      Operating MetricsView all

      Healthcare Workers Trained

      199K
      50.5%

      FY, 2021

      New Phase I Projects

      3

      Q2, 2022

      New Phase II Projects

      1
      75.0%

      Q2, 2022

      LocationsView all

      103 locations detected

      • Cambridge, England HQ

        United Kingdom

        1 Francis Crick Ave

      • Gaithersburg, MD

        United States

        1 Medimmune Way

      • Gaithersburg, MD

        United States

        200 Orchard Ridge Dr

      • Gaithersburg, MD

        United States

        950 Wind River Ln

      • South San Francisco, CA

        United States

        121 Oyster Point Blvd

      • Waltham, MA

        United States

        35 Gatehouse Dr

      and 97 others

      AstraZeneca Financials

      Summary Financials

      Revenue (Q1, 2026)
      $15.3B
      Gross profit (Q1, 2026)
      $14.2B
      Net income (Q1, 2026)
      $3.1B
      Cash (Q1, 2026)
      $7.6B
      EBIT (Q1, 2026)
      $4.2B
      Enterprise value
      $28.4B

      Footer menu